FX Weekly Recap: June 16 – 20, 2025
Major central bank meetings and escalating Middle East tensions created forex market volatility, with Canadian dollar suffering worst weekly performance among currencies.
Similar Posts
USD/JPY Forecast: BoJ Hawks Gain Ground, US Risks Mount – Forex Crunch
The USD/JPY forecast remains bearish as the BOJ tilts closer to a rate hike. The risk of a US government shutdown and higher JGB yields support the bearish narrative in USD/JPY. Markets are now watching the JOLTS job opening data, along with key speeches, for further impetus. The Japanese yen gained solid ground on Tuesday,…
The Analytical Overview of the Main Currency Pairs on Natural gas prices fell by 4%. Oil also remains under pressure from weak demand
At Monday’s close, the Dow Jones (US30) Index was up 1.16%, while the S&P 500 (US500) Index added 1.16%. The NASDAQ Technology Index (US100) closed positive 1.30%. A rise in chip company stocks provided support for the broader market. In addition, positive corporate news drove the stock higher. Palantir Technologies (PLTR) closed higher by more…
Australian Dollar rises as US Dollar falls due to rising concerns over Fed’s independence
The Australian Dollar rose as investor sentiment wavered following renewed criticism from President Trump targeting Fed Chair Powell. White House’s Hassett stated that Trump is considering his authority to remove Powell from his position. China continues to stand against Trump’s hardline tariff approach, adding to global market uncertainty. The Australian Dollar (AUD) extends its gains…
ASIC Sues HSBC Australia for Failure to Protect Customers From Scams
On Monday the Australian Securities and Investments Commission (ASIC) said it has launched legal action against HSBC Bank Australia. The regulator alleges widespread failures in protecting customers from scams. ASIC argues the bank did not have adequate controls in place to prevent or detect unauthorised payments and failed to investigate scam reports within the specified…
BioAge Plunges Over 60% â What’s Weighing Down The STRIDES Trial Of Its Obesity Drug?
Shares of BioAge Labs Inc. (BIOA) experienced a dramatic decline of over 60% in after-hours trading on Friday, following the company’s announcement to cease the ongoing STRIDES trial.The STRIDES trial, a phase II study, was evaluating BioAge’s lead drug candidate, Azelaprag, in conjunction with Eli Lilly’s weight management medication, tirzepatide, for the treatment of obesity.The…
Mexico peso set to slip after expiry of US tariff hike freeze: Reuters poll
Mexico peso set to slip after expiry of US tariff hike freeze: Reuters poll Source link
